IN THE half-century which has elapsed since the original description of keratosis blennorrhagica by Vidal1 in 1893, it has become generally agreed that this disease represents a distinct clinical entity. In 1942 Keim2 analyzed the disease from an etiologic standpoint and described the fundamental histologic changes. Since that time numerous investigators have anvanced methods of treatment; these have in the main been directed against the general infection, local treatment proving to be of little value.
Among the therapeutic measures reported favorably are intravenous injections of 1 per cent solution of merbromin N. F., (mercurochromeR), by Willmott3 in 1926, and the use of autogenous vaccines, by Scholtz,4 about one year later. Downing5 reported rapid recovery in a patient following double vesiculectomy and prostatotomy. Sherman, Blumenthal and Heidenreich6 stressed the importance of treating the primary focus and stated the opinion that local treatment of the